Updates in the Management of Graves Disease in Children
Graves disease (GD) is the primary cause of hyperthyroidism in children. The standard management options—namely, antithyroid drugs (ATD), radioactive iodine, and surgery—have not changed for many years. Although ATD therapy is often the fir...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ewha Womans University College of Medicine
2023-12-01
|
| Series: | The Ewha Medical Journal |
| Subjects: | |
| Online Access: | http://www.e-emj.org/archive/view_article?pid=emj-46-s1-31 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Graves disease (GD) is the primary cause of hyperthyroidism in children. The
standard management options—namely, antithyroid drugs (ATD), radioactive
iodine, and surgery—have not changed for many years. Although ATD therapy
is often the first-line treatment for pediatric patients, the low likelihood of
spontaneous remission means that most children will require a more permanent
solution. Recent clinical trials and systematic reviews have shed light on the
long-term outcomes of ATD therapy, radioactive iodine, and surgical
interventions in managing pediatric GD. Additionally, novel therapies aimed at
B-cells or the thyroid-stimulating hormone receptor, both implicated in the
pathogenesis of GD, are under investigation. However, their definitive role in
treating childhood GD has yet to be established. This review will cover the
latest developments in the treatment of childhood GD, including information on
emerging targeted therapies. |
|---|---|
| ISSN: | 2234-2591 |